Self-Assembled Nanoparticles with E Protein Domains I and II of Duck Tembusu Virus Can Induce a More Comprehensive Immune Response Against the Duck Tembusu Virus Challenge.

Duck Tembusu virus (DTMUV) is a pathogenic flavivirus that causes a substantial drop in egg production and severe neurological disorders in domestic waterfowl. Self-assembled ferritin nanoparticles with E protein domains I and II (EDI-II) of DTMUV (EDI-II-RFNp) were prepared, and its morphology was observed. Two independent experiments were conducted. First, Cherry Valley ducks aged 14 days were vaccinated with EDI-II-RFNp, EDI-II, and phosphate buffered solution (PBS, pH 7.4), and special and virus neutralization (VN) antibodies, interleukin 4 (IL-4) and interferon gamma (IFN-γ) in serum, and lymphocyte proliferation were detected. Second, the vaccinated ducks with EDI-II-RFNp, EDI-II, and PBS were injected with virulent DTMUV, clinical signs at 7 days postinfection (dpi) were observed, and mRNA levels of DTMUV in the lungs, liver, and brain at 7 and 14 dpi were detected. The results showed near-spherical nanoparticles EDI-II-RFNp with a 16.46 ± 4.70 nm diameters. The levels of specific and VN antibodies, IL-4 and IFN-γ, and lymphocyte proliferation in the EDI-II-RFNp group were significantly higher than those in the EDI-II and PBS groups. In the DTMUV challenge test, clinical signs and mRNA levels in tissue were used to evaluate protection of EDI-II-RFNp. EDI-II-RFNp-vaccinated ducks showed milder clinical signs and lower levels of DTMUV RNA in the lungs, liver, and brain. These results indicate that EDI-II-RFNp effectively protects ducks against the DTMUV challenge and could be a vaccine candidate to provide an effective and safe method for preventing and controlling DTMUV infection.